Synergistic Cytotoxic Effect of Honey Bee Venom and Cisplatin on Tongue Squamous Cell Carcinoma Cell Line
DOI:
https://doi.org/10.3889/oamjms.2021.7672Keywords:
Honey bee venom, Cisplatin, SCC-25 cells, ApoptosisAbstract
BACKGROUND: Tongue cancer is one of the most common head and neck cancers in the world. Nowadays, natural compounds are important resources of many anti-cancer drugs. Venom from honey bees possesses potent anti-cancer activities. Cisplatin is a chemotherapeutic drug that has been used for decades to treat cancer cells. Recently, combination therapy has been a popular treatment choice for cancer patients.
AIM: This study was conducted to evaluate the synergistic cytotoxic effect of honey bee venom (BV) and cisplatin on tongue squamous cell carcinoma 25 (SCC-25) cell lines.
METHODS: The cytotoxic effect was determined using methyl thiazol tetrazolium assay, microscopic examination, real-time polymerase chain reaction (RT-PCR), and statistical analysis.
RESULTS: The findings revealed that the cytotoxic potential of the tested drugs on SCC-25 cells was dose-dependent. Microscopic examination showed that BV and cisplatin alone and in combination mainly produced apoptotic cell death. Regarding RT-PCR results, P53 and caspase-3 expression levels were significantly increased in SCC-25-treated cells (p = 0.0001).
CONCLUSION: The combined use of BV and cisplatin induced a marked synergistic cytotoxic effect on SCC-25 cell line.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. http://doi.org/10.3322/caac.21660 PMid:33538338
Yosefof E, Hilly O, Stern S, Bachar G, Shpitzer T, Mizrachi A. Squamous cell carcinoma of the oral tongue: Distinct epidemiological profile disease. Head Neck. 2020;42(9):2316-20. http://doi.org/10.1002/hed.26177 PMid:32320105
Farah CS. Oral mucosal malignancies. In: Balasubramaniam R, McCullough MJ, editors. Contemporary Oral Medicine: A Comprehensive Approach to Clinical Practice. Cham: Springer International Publishing; 2019. p. 1249-436.
Cramer JD, Burtness B, Le AT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16(11):669-83. http://doi.org/10.1038/s41571-019-0227-z PMid:31189965
Rayan A, Raiyn J, Falah M. Nature is the best source of anticancer drugs: Indexing natural products for their anticancer bioactivity. PLoS One. 2017;12(11):e0187925. http://doi.org/10.1371/journal.pone.0187925 PMid:29121120
Frangieh J, Salma Y, Haddad K, Mattei C, Legros C, Fajloun Z, et al. First characterization of the venom from Apis Mellifera syriaca, a honey bee from the Middle East region. Toxins. 2019;11(4):191. http://doi.org/10.3390/toxins11040191 PMid:30935025
Kim KH, Kim M, Lee J, Jeon HN, Kim SH, Bae H. Comparison of the protective effects of bee venom extracts with varying PLA2 compositions in a mouse model of parkinson’s disease. Toxins. 2019;11(6):358. http://doi.org/10.3390/toxins11060358 PMid:31248167
El Bakary NM, Alsharkawy AZ, Shouaib ZA, Barakat EM. Role of bee venom and melittin on restraining angiogenesis and metastasis in γ-irradiated solid ehrlich carcinoma-bearing mice. Integr Cancer Ther. 2020;19:1534735420944476.
Yaacoub C, Rifi M, El-Obeid D, Mawlawi H, Sabatier JM, Coutard B, et al. The cytotoxic effect of Apis mellifera venom with a synergistic potential of its two main components melittin and PLA2 on colon cancer HCT116 cell lines. Molecules. 2021;26(8):2264. http://doi.org/10.3390/molecules26082264 PMid:33919706
Wehbe R, Frangieh J, Rima M, El Obeid D, Sabatier JM, Fajloun Z. Bee Venom: Overview of main compounds and bioactivities for therapeutic interests. Molecules (Basel, Switzerland). 2019;24(16):2997. http://doi.org/10.3390/molecules24162997 PMid:31430861
Qi L, Luo Q, Zhang Y, Jia F, Zhao Y, Wang F. Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol. 2019;32(8):1469-86. http://doi.org/10.1021/acs.chemrestox.9b00204 PMid:31353895
Kleih M, Böpple K, Dong M, Gaißler A, Heine S, Olayioye MA, et al. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis. 2019;10(11):1-12.
Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: A review for chemists. Dalton Trans. 2018;47(19):6645-53. http://doi.org/10.1039/c8dt00838h PMid:29632935
Gajski G, Čimbora-Zovko T, Rak S, Osmak M, Garaj-Vrhovac V. Antitumour action on human glioblastoma A1235 cells through cooperation of bee venom and cisplatin. Cytotechnology. 2016;68(4):1197-205. http://doi.org/10.1007/s10616-015-9879-4 PMid:25916941
Ciccarone F, De Falco P, Ciriolo MR. Aconitase 2 sensitizes MCF-7 cells to cisplatin eliciting P53-mediated apoptosis in a ROS-dependent manner. Biochem Pharmacol. 2020;180:114202. http://doi.org/10.1016/j.bcp.2020.114202 PMid:32818504
Yadav P, Yadav R, Jain S, Vaidya A. Caspase-3, a primary target for natural and synthetic compounds for cancer therapy. Chem Biol Drug Des. 2021;98(1):144-65. http://doi.org/10.1111/cbdd.13860 PMid:33963665
Xu X, Lai Y, Hua ZC. Apoptosis and apoptotic body: Disease message and therapeutic target potentials. Biosci Rep. 2019;39(1):BSR20180992. http://doi.org/10.1042/BSR20180992 PMid:30530866
Arandjelovic S, Ravichandran KS. Phagocytosis of apoptotic cells in homeostasis. Nat Immunol. 2015;16(9):907-17. http://doi.org/10.1038/ni.3253 PMid:26287597
Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D’Orazi G. Apoptosis as anticancer mechanism: Function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY), 2016;8(4):603. http://doi.org/10.18632/aging.100934 PMid:27019364
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. http://doi.org/10.3322/caac.21262 PMid:25651787
Pires FR, Ramos AB, de Oliveira JB, Tavares AS, da Luz PS, dos Santos TC. Oral squamous cell carcinoma: Clinicopathological features from 346 cases from a single oral pathology service during an 8-year period. J Appl Oral Sci. 2013;21(5):460-7. http://doi.org/10.1590/1679-775720130317 PMid:24212993
Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141-60. http://doi.org/10.20517/cdr.2019.10 PMid:34322663
Carpena M, Nuñez-Estevez B, Soria-Lopez A, Simal-Gandara J. Bee Venom: An updating review of its bioactive molecules and its health applications. Nutrients. 2020;12(11):3360. http://doi.org/10.3390/nu12113360 PMid:33142794
Lee HS, Kim YS, Lee KS, Seo HS, Lee CY, Kim KK. Detoxification of bee venom increases its anti-inflammatory activity and decreases its cytotoxicity and allergenic activity. Appl Biochem Biotechnol. 2021;193(12):4068-82. http://doi.org/10.1007/s12010-021-03653-2 PMid:34542820
Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Design Dev Ther. 2016;10:1885. http://doi.org/10.2147/DDDT.S106412 PMid:27354763
Alonezi S, Tusiimire J, Wallace J, Dufton MJ, Parkinson JA, Young LC, et al. Metabolomic profiling of the synergistic effects of melittin in combination with cisplatin on ovarian cancer cells. Metabolites. 2017;7(2):14. http://doi.org/10.3390/metabo7020014 PMid:28420117
He Y, Zhu Q, Chen M, Huang Q, Wang W, Li Q, et al. The changing 50% inhibitory concentration (IC50) of cisplatin: A pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer. Oncotarget. 2016;7(43):70803-21. http://doi.org/10.18632/oncotarget.12223 PMid:27683123
Goldar S, Khaniani MS, Derakhshan SM, Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 2015;16(6):2129-44. http:// doi.org/10.7314/apjcp.2015.16.6.2129 PMid:25824729
Kiraz Y, Adan A, Yandim MK, Baran Y. Major apoptotic mechanisms and genes involved in apoptosis. Tumor Biol. 2016;37(7):8471-86. http://doi.org/10.1007/s13277-016-5035-9 PMid:27059734
Follis AV, Llambi F, Merritt P, Chipuk JE, Green DR, Kriwacki RW. Pin1-induced proline isomerization in cytosolic P53 mediates BAX activation and apoptosis. Mol Cell. 2015;59(4):677-84. http://doi.org/10.1016/j.molcel.2015.06.029 PMid:26236013
Jo DW, Kim YK, Yun PY. The influence of P53 mutation status on the anti-cancer effect of cisplatin in oral squamous cell carcinoma cell lines. J Korean Assoc Oral Maxillofac Surg. 2016;42(6):337-44. http://doi.org/10.5125/jkaoms.2016.42.6.337 PMid:28053903
Downloads
Published
How to Cite
License
Copyright (c) 2020 Sabreen Amar, Amr Helmy Mustafa El-Bolok, Sherif Farouk El-Gayar, Maii Ibrahim Sholkamy (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)
